ClinicalTrials.gg
CompletedNCT06849843Updated Sep 12, 2025

A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.

A Phase 2 interventional study of Efsubaglutide Alfa Injection and Efsubaglutide Alfa Injection in Type2 Diabetes, sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Completed at 10 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
589th of 769
59 · median 192
Started
2024
with 83 others
Phase 2
61 of 913
14 open now
Registered
722nd of 913
by date

Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 589th largest by enrollment of the 769 interventional ones that give a count, is one of 84 that started in 2024, is one of 61 in phase 2, and was the 722nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 913 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This is a study to evaluate the impact and efficacy of Efsubaglutide Alfa injection 3mg QoW on the treatment of type 2 diabetes patients with poor glycemic control after dietary and exercise intervention.

Primary objective:

To evaluate the effect and role of continuous treatment with 3mg of Efsubaglutide Alfa QoW and 1mg of Efsubaglutide Alfa QW for 12 weeks on HbA1c in T2DM patients with poor glycemic control after dietary and exercise intervention.

Secondary objectives:

  1. To evaluate the effect of continuous treatment with 3mg of Efsubaglutide Alfa QoW for 12 weeks on glucose variability (change in time in range (TIR) relative to baseline) in T2DM patients with poor glycemic control after dietary and exercise intervention.
  2. To evaluate the effect of continuous treatment with 3mg of Efsubaglutide Alfa QoW for 12 weeks on drug exposure (relative to 1mg QW) in T2DM patients with poor glycemic control after dietary and exercise intervention.
  3. To evaluate the effect of continuous treatment with 3mg of Efsubaglutide Alfa QoW for 12 weeks on fasting plasma glucose (FPG) in T2DM patients with poor glycemic control after dietary and exercise intervention.
03

Conditions studied

  • Type2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged from 18 to 75;
  2. Type 2 diabetes diagonsed at least 8 weeks and has not received any glucose-lowering medication within 8 weeks prior to screening;
  3. During screening, : 7.0% ≤ HbA1c ≤ 11.0%;
  4. Before randomization : 7.0% ≤ HbA1c ≤ 11.0%;
  5. During screening and before randomization: FPG\< 13.9 mmol/L
  6. 24 kg/m2 ≤ ≤ 40 kg/m2;
  7. Without birth plan and voluntarily take effective measures;
  8. Fully understood the study, voluntarily entered the study and signed the .

Exclusion criteria

Exclusion Criteria:

  1. Diabetes other than Type 2;
  2. Any DPP-4 inhibitors and / or GLP-1 analogues were used within 3 months before screening;
  3. Continuous use of insulin for more than 14 days in the previous year;
  4. C-Peptide \<0.3 nmol/L;
  5. Diabetic ketoacidosis, diabetic lactic acidosis or hyperosmolar non ketonic diabetic coma occurred within 6 months before screening;
  6. Unstable proliferative retinopathy or macular lesion, severe diabetic neuropathy, intermittent claudication or diabetic foot occurred within 6 months before screening;
  7. Severe hypoglycemia occurred within 6 months before screening
  8. Severe trauma infection or operation within one month before screening;
  9. Blood donation or massive blood loss or transfusion within 3 months ;
  10. Suspected active infection ;
  11. Growth hormone therapy was performed within 6 months before screening;
  12. Patients having received continuous ≥ 7 days through within 2 months ;
  13. Use any drugs or surgery with weight control effect within 2 months;
  14. weight change of more than 5% within 3 months;
  15. mean systolic pressure (SBP) ≥ 160mmhg and / or DBP ≥ 90 mmHg at screening, or new/changed antihypertensive drugs or adjusted dosage of antihypertensive drugs within 4 weeks before screening or before induction period
  16. with a history of severe cardiovascular disease, high risk of stroke/stroke within 6 months before screening;
  17. with a history of acute or chronic pancreatitis, symptomatic gallbladder , pancreatic injury and other risk factors for pancreatitis, or with blood amylase and/or blood lipase ≥1.5 times the (ULN) at the time of screening or before randomization;
  18. Calcitonin level ≥50 ng/L (pg/mL) during screening;
  19. with a history of medullary thyroid cancer, multiple endocrine neoplasm (Men) 2A or 2B syndrome, or related family history;
  20. with abnormal gastric emptying , severe chronic gastrointestinal diseases , long-term use of drugs that have a direct impact on gastrointestinal peristalsis , or having undergone gastrointestinal surgery within 6 months before screening, are not suitable to participate in this clinical study according to the evaluation of the researchers;
  21. suffering from hematological diseases or any disease causing hemolysis or erythrocyte instability ;
  22. Uncontrolled hyperthyroidism or hypothyroidism;
  23. with hemoglobinopathy that may affect the determination of levels;
  24. , -Ab, -Ab, TPAb or COVID-19 nucleic acid tested positive;
  25. serious mental illness;
  26. drinking more than 14 standard units weekly within 6 months before screening ;
  27. a history of organ transplantation or other acquired or congenital immune system diseases;
  28. allergic to the active ingredients (GLP-1 and GLP-1 analogues) of the study drug;
  29. clear for the use of metformin;
  30. Any of the following conditions: the pacemaker was installed when screened; no pacemaker was installed, but 12 lead showed degree II or III atrioventricular block, long syndrome or QTc interval ≥ 450ms (fridericia formula was used to calculate QTCF); Patients with New York Heart Function Classification III or IV; Or other abnormal cardiac function with clinical significance that is not suitable for clinical research judged by researchers;
  31. acute or chronic viral hepatitis, or whose laboratory examination indexes meet one of the following criteria at the time of screening or before randomization : (ALT) level ≥ 2.5 fold ULN, aspartate aminotransferase (AST) ≥ 2.5 fold ULN, fasting triglyceride (TG) > 5.7 mmol/L or 500 mg/dl; the (EGFR) \< 60 ml/min/1.73 m2 was calculated by CKD-EPI (epi - (SCR)) formula;
  32. participated in clinical trials of other drugs or devices within 3 months before screening;
  33. Medication compliance in the lead-in period was ≤ 50% ;
  34. Any other situation that researchers think may affect the patients' or compliance with the trial protocol, or the patients' participation in the trial may affect the trial results or their own safety.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    3mg of Efsubaglutide Alfa QoW

    Drug: Efsubaglutide Alfa Injection

  • Active comparator
    1mg of Efsubaglutide Alfa QW

    Drug: Efsubaglutide Alfa Injection

Interventions

06

What researchers measure

Primary outcomes

  1. HbA1c

    The change in mean HbA1c concentrations (%)from baseline with Efsubaglutide Alfa 3mg QoW versus Efsubaglutide Alfa 1mg QW

    Time frame: 12 weeks

Secondary outcomes

  1. TIR

    Changes in the percentage of time in range (TIR) relative to baseline

    Time frame: 12 weeks

  2. HbA1c<7.0% and <6.5%

    The proportion of participants who achieved HbA1c target (HbA1c\<7.0% and \<6.5% Patient percentage)

    Time frame: 12 weeks

  3. fasting lipid profiles

    Changes in fasting lipid(TC/TG/HDL-C/LDL-C) profiles relative to baseline(mmol/L)

    Time frame: 12 weeks

  4. weight

    Weight change from baseline(kg)

    Time frame: 12 weeks

  5. waist circumference

    Absolute changes in waist circumference(cm) from baseline

    Time frame: 12 weeks

  6. hip circumference

    Absolute changes in hip circumference(cm) from baseline

    Time frame: 12 weeks

  7. waist-to-hip ratio (WHR)

    Absolute changes in waist-to-hip ratio (WHR) from baseline

    Time frame: 12 weeks

  8. salvage treatment

    Percentage of subjects receiving salvage treatment(%)

    Time frame: 12 weeks

  9. body fat composition

    Changes in body fat composition from baseline

    Time frame: 12 weeks

  10. FPG

    Changes in FPG (mmol/L) relative to baseline

    Time frame: 12 weeks

07

Study locations

10 sites
  • Nanjing First Hospital
    Nanjing, Jiangsu 210008, China
  • CangZhou Hospital of Integrated TCM and Western Medicine in Hebei Province
    Cangzhou, China
  • Huzhou Central Hospital
    Huzhou, China
  • Jiangsu Province Offical Hospital
    Nanjing, China
  • Ningbo First Hospital
    Ningbo, China
  • Ningbo Medical Center Lihuili Hospital
    Ningbo, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, China
  • The Second Affiliated Hospital of Wenzhou Medical University
    Wenzhou, China
  • Wenzhou Central Hospital
    Wenzhou, China
  • Zibo Municipal Hospital
    Zibo, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in May 2025, 5 months.

Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 5 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 27, 2025
StartActual
Dec 18, 2024
Primary completionActual
May 29, 2025
CompletionActual
May 29, 2025
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06849843
Lead sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Feb 27, 2025
Start date
Dec 18, 2024
Primary completion
May 29, 2025
Completion
May 29, 2025
Last update
Sep 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efsubaglutide alfa

Start the discussion